FDA Approves Nivolumab for Renal Cell CarcinomaFDA Approves Nivolumab for Renal Cell Carcinoma
The immunotherapy is the first treatment to show a survival benefit as a second-line therapy in patients with advanced disease. FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer & Oncology | Carcinoma | Hematology | Immunotherapy | Kidney Cancer | Renal Cell Carcinoma